AHA 2024: Phase III BROOKLYN trial – safety and efficacy of obicetrapib in HeFH patients
During the Phase III BROOKLYN trial, patients were randomly assigned in a 2:1 ratio to receive either obicetrapib 10mg or a matching placebo, orally, once daily for 52 weeks.
